About Actgen Pharma Private Limited
Data last updated: 01 January 2026
Actgen Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 08 March 2008, the company has been in operation for over 18 years.
Registered with ROC Mumbai under CIN U24239MH2008PTC179859.
Capital: an authorised share capital of ₹9 Cr and a paid-up capital of ₹9 Cr. It is led by directors Kantilal Mangalchand Hiran and Dariyadevi Kantilal Hiran.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Shop No. 45 1St Floor Rustomjee Ease Zone Goregaon Mulund Link Road Malad (West), Mumbai, Maharashtra, India – 400062.
As per the financials filed for FY 2023, the company reported a revenue of ₹10.17 Cr, reflecting significant growth compared to the previous year.
The company is associated with 1 brand - Actgen Pharma. As per MCA filings, the company has satisfied charges of ₹72 Cr on record.
The current compliance status is marked as active non-compliant by the Registrar of Companies. For more details, the company can be reached via its website actgen.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressShop No. 45 1St Floor Rustomjee Ease Zone Goregaon Mulund Link Road Malad (West), Mumbai, Maharashtra, India – 400062
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Actgen Pharma Private Limited
Actgen Pharma Private Limited operates one associated brand: ActGen Pharma. These brands represent Actgen Pharma Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufactures active pharmaceutical ingredients (APIs). | actgen.in |
Competitors & Alternatives of Actgen Pharma Private Limited
Brands and companies operating in the same space as Actgen Pharma Private Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Actgen Pharma Private Limited
Actgen Pharma Private Limited operates primarily in the manufacturing sector. The company has 2 registered business activity segments, reflecting its diverse operational portfolio.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| ********* | Manufacturing | ********* | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
| ********* | Manufacturing | ********* | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Actgen Pharma Private Limited
Actgen Pharma Private Limited is audited by RDJ and Associates LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| RDJ and Associates LLP | blur-value | blur-value | blur-value |
Board of Directors of Actgen Pharma Private Limited
Actgen Pharma Private Limited is currently managed by 2 directors, with 8 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Kantilal Mangalchand Hiran
Also directs:
Sunflower Trading And Investment Pvt Ltd
|
Director | 05 Sep 2023 | 2 Years 10 Months | Current |
| Dariyadevi Kantilal Hiran | Director | 06 Nov 2023 | 2 Years 8 Months | Current |
Financials of Actgen Pharma Private Limited FY 2025 filings available
Actgen Pharma Private Limited reported revenue of ₹10.17 Cr (up 980.20% YoY) for FY 2023. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Actgen Pharma Private Limited
As of FY 2023, Actgen Pharma Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Actgen Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jan 2010 | Bank of India | ₹27 Cr | Satisfied |
| 27 Feb 2009 | Bank of India | ₹27 Cr | Satisfied |
| 27 Nov 2008 | Bank of India | ₹18 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Actgen Pharma Private Limited
Actgen Pharma Private Limited has a workforce of 0 employees as of Apr 06, 2024.
Employee Count & EPFO Data of Actgen Pharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Actgen Pharma Private Limited
GSTIN & GST Filing Data of Actgen Pharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Actgen Pharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Actgen Pharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Actgen Pharma Private Limited
MSME Payment Delays by Actgen Pharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Actgen Pharma Private Limited
Subsidiaries & Group Companies of Actgen Pharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Actgen Pharma Private Limited with ownership details.
MCA Filings & Documents of Actgen Pharma Private Limited
MCA Filings & Documents of Actgen Pharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Actgen Pharma Private Limited
Frequently Asked Questions about Actgen Pharma Private Limited
Actgen Pharma Private Limited is an active private limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 08 March 2008 (18+ years old) and is registered under CIN U24239MH2008PTC179859.
Actgen Pharma Private Limited reported revenue of ₹10.17 Cr for FY 2023 (up 980.20% YoY).
The current directors of Actgen Pharma Private Limited are:
The primary industry of Actgen Pharma Private Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Actgen Pharma Private Limited can be reached at the registered office: Shop No. 45 1St Floor Rustomjee Ease Zone Goregaon Mulund Link Road Malad West, Mumbai, Maharashtra, India – 400062, or through the website actgen.in.
The authorised capital is ₹9 Cr, and the paid-up capital is ₹9 Cr.